OROPRO™

PACKAGE INSERT
DONATED HUMAN TISSUE

READ THIS ENTIRE PACKAGE INSERT CAREFULLY PRIOR TO USE. RESTRICTED TO USE BY OR ON THE ORDER OF A LICENSED HEALTHCARE PROFESSIONAL (physician, dentist, podiatrist, optometrist, nurse practitioner or physician assistant).

DESCRIPTION

OROPRO™ is a versatile product that is derived from donated human birth tissue. The allograft contains tissue elements that are inherent to an umbilical cord homogenate, which include but are not limited to collagen substrates and extracellular matrix. This allograft provides natural collagen scaffold to support replacement by endogenous tissue. The birth tissue is obtained with consent from cesarean section delivery. OROPRO™ is processed using aseptic techniques and stored under cryopreserved conditions and cannot be sterilized. The allograft is packaged in an aseptic vial and sealed in packaging consisting of a conical tamper proof seal tube within a tear pouch configuration.

INTENDED USE

OROPRO™ is intended for ***HOMOLOGOUS USE*** as an additive for applications associated with soft-tissue procedures.

CONTRAINDICATIONS

OROPRO™ has no known contraindications.

STORAGE AND SHIPPING

OROPRO™ must be stored **at ≤-130°C** until time for use**.** It is the responsibility of the Tissue Dispensing Service, Tissue Dispensing Intermediary, and/or End-User Clinician to maintain the allograft in appropriate storage conditions prior to further distribution or use and to track expiration dates accordingly. Appropriate inventory control should be maintained so that the allograft with an earlier expiration date is preferentially used and expiration is avoided. Do not let this product thaw until it is time to use. **Once thawed this product must be used within 15 minutes** or discarded, it **CANNOT BE RE-FROZEN**. This product is shipped in a validated shipping container with dry ice or equivalent at -40°C or colder. It must arrive within the validated time for the container. The product should be transferred to an appropriate cold storage location prior to the expiration of the shipping container.

WARNINGS

The donor of OROPRO™ has been screened and tested for relevant communicable diseases and disease agents in compliance with the FDA regulations, relating to human cells, tissues, and cellular and tissue-based products (21 CFR part 1271). OROPRO™ was processed using aseptic techniques and microbiologically tested. Although all efforts have been made to ensure the safety of the allograft, there is no assurance that this allograft is free from all infectious diseases or microbial contamination.

Same and similar potential medical/surgical conditions or complications that apply to any surgical procedure may occur during or following implantation of this allograft. The physician or surgeon is responsible for informing the patient of the risks associated with their treatment and the possibility of complications or adverse reactions. As with any human tissue implant, the potential for transmission of infectious agents may exist.

Localized immunological response; injection site tenderness potentially may occur; allograft contains less than 10% DMSO as cryoprotectant. Patients with history of sulfur sensitivity should consider taking precautions prior to injection.

FOR USE IN ONE PATIENT, ON A SINGLE OCCASION ONLY

DONOR ELIGIBILITY

The qualified donated human placental tissue was recovered by a regulated procurement agency, after informed consent and screening for healthy mothers scheduled for elective Caesarian deliveries. The donor consents to the collection of this tissue, provided that its collection does not cause any harm to their infants. The donated tissue was processed using aseptic techniques in accordance with federal, state, and/or international regulations. The donor has been screened and tested for communicable disease risks and other exclusionary medical conditions. The results of the donor screening and testing has been reviewed by the Medical Director of BioStem Life Sciences, Inc. and the donors have been deemed suitable for transplantation. Communicable diseases testing has been performed by an FDA-registered laboratory certified to perform such testing on human specimens under the Clinical Laboratory Improvement Amendments of the 1988 (42 U.S.C. 263a) and 42 CFR part 493, or equivalent and registered with the US FDA for donor testing. The results from the following test criteria have been found to be nonreactive or negative:

Required Donor Testing All results must be reported negative or non-reactive to allow release	**Allograft Release Testing** For release testing on final product, Bioburden testing must present with "No Growth" results along with Endotoxin results ≤ 0.5 EU/ml.
Blood Test	
HIV-1/ HIV-2 Antibody	
Hepatitis C Virus Antibody	
Hepatitis B Surface Antigen/ HBV NAT	
Hepatitis B Core Antibody (total)	**NOTE:** Screening for exposure to other viruses or parasites may have been completed. A negative / non-reactive result is not required, all results are evaluated by Medical Director: Cytomegalovirus CMV-AB (IgG&IgM) Epstein Barr EBV Ab (IgG-IgM) Toxoplasma gondii Toxoplasma Ab (IgG-igM) Trypansoma Cruzi T.Cruzi Ab (IgG-IgM), Lyme.
Syphilis	
Human T-Cell Lymphotropic Virus 1 Antibody	
Human T-Cell lymphotropic Virus 2 Antibody	
HIV-1 / HCV NAT-TMA	
West Nile Virus (WNV)	
At the time of procurement, cultures of the tissue are taken and grown out for evaluation. Donor tissue with cultures testing positive for the following microorganisms are deferred: • *Clostridium* • *Streptococcus pyogenes* (group. A strep.) • *Enterococcus* • Fungi (mold or yeast phase)	

As a screening tool in addition to communicable diseases, the donor completed a social and medical questionnaire. The medical director of BioStem Life Sciences, Inc. has reviewed the results of testing and determined the donor has met all eligibility requirements. The physician utilized available relevant information which may have included, but was not limited to: donor interview, medical/hospital records, donor physical assessment, infectious disease test results, radiology/pathology and other records if available and pertinent. Recipient records must be maintained for the purpose of tracing tissue post-transplant per JCAHO and FDA requirements.

PRECAUTIONS

Prior to use, the surgeon must become familiar with the implant. The implant should **NOT** be used in surgical sites where an active infection is present, in necrotic sites or in sites with poor perfusion. The implant should **NOT** be used under high tension or pressure. Biostem Life Sciences does **NOT** recommend use in the spinal canal, disc, or epidural space. Appropriate placement of the allograft is critical for successful outcomes.

ADVERSE EVENTS

Allogeneic cells or tissue can induce immunological response in the recipient. The possibility that a patient may develop alloantibodies should be considered for any patient who might be a future recipient of allograft tissue or cells.

Possible adverse events may include immunologic response, transmission of disease of unknown etiology and transmission of infectious agents including but not limited to HIV, hepatitis, syphilis, or microbial contaminants.

INSTRUCTIONS FOR USE

It is important to read and understand the following instructions prior to clinical use. Improper preparation technique may adversely affect handling properties.

General Instructions

1. For use on a single visit/surgery/episode for a single patient, this product cannot be shared or stored after thawing.
2. Remove the tube containing vial from plastic bag. Inspect the packaging and labeling materials carefully:
3. Do not use past expiration date specified on the product label.
    a. Do not use if the implant or packaging is damaged.
    b. Do not use if there are discrepancies in label information
    c. Photograph and document all packages with compromised sterile barrier, lacking allograft, wrong size or wrong labeling
    d. To prevent contamination of the implant, use sterile technique for preparation and implantation.
    e. Do not sterilize or re-freeze
    f. Use standard practices for handling and disposal of human tissue
    g. Promptly report all complaints and patient adverse events to BioStem Life Sciences.
    h. Take photographs if possible, to document any concerns.
4. Open outer vial, remove inner vial, hold upright.
5. Thaw allograft by holding the inner vial in your hand, do not turn upside down or shake, thawing takes approximately 3 minutes.
6. Draw the allograft out of the vial with a sterile 18g or larger needle into a syringe.
7. **Packaging is not sterile**, if used in a surgical environment, use a sterile 18g or larger needle to withdraw the allograft out of the vial into a sterile syringe. The contents of the vial are **aseptic**, the outside of the vial was prepared in an aseptic environment, but it is **not sterile**.
8. Apply the allograft using a 18g or larger needle into and around the targeted area.
9. Fill out the Tissue Tracking Card (even if the allograft is discarded) and return to BioStem Life Sciences. This information is kept confidential and used only for implant tracking.
10. Follow your patient, inform BLS of any adverse events, concerns or questions immediately.

RECIPIENT INFORMATION

Per FDA (21 CFR 1271.290) patient records must be maintained for the purpose of traceability from the donor to the patient. It is the responsibility of the End-User or the Clinician to provide BioStem Life Sciences, Inc. with information pertaining to the traceability of the allograft used. For this purpose, the postage paid Tissue Tracking card (TTC) is provided with the allograft. Once the allograft is used, peel off the small product labels provided on the product packaging and affix on the TTC and applicable patient records. Complete the TTC and mail to BioStem Life Sciences, Inc., or scan and e-mail to TTC@biostemlife.com. Even if the tissue has been discarded for any reason, a completed TTC with the allograft identification must be returned to BioStem Life Sciences, Inc.

ADVERSE OUTCOME AND COMPLAINT REPORTING

Adverse outcomes potentially attributed to OROPRO™ or other complaints must be promptly reported to Biostem Life Sciences:

BioStem Life Sciences, Inc.
Quality Assurance Department
2836 Center Port Circle,
Pompano Beach, Florida
Office: (954) 406-5275

RETURN GOODS POLICY

This allograft processed and packaged for surgical implantation, is unique and does not constitute a product under liability laws. No implied warranties of merchantability or fitness for a particular purpose are applicable. No implied warranties exist as to defects in biologics, which cannot be detected, removed, or prevented by reasonable use of available scientific procedures or techniques. Furthermore, all warranties are disclaimed, whether expressed or implied by operation of law or otherwise including all implied warranties of merchantability or fitness for a particular purpose. If product is unusable please document why, take photographs of any damage, defects, or deficiencies and forward this information to

Processing and donor suitability performed by:
BioStem Life Sciences, Inc.

BioStem Life Sciences, Inc.,
2836 Center Port Circle,
Pompano Beach, Florida
Manufacturer/Processor
FDA registration 3013239405

Disclaimer: It is the responsibility of the Tissue Dispensing Service, Tissue Distribution Intermediary, and/or End-User clinician to maintain tissue intended for transplant in appropriate, labeled, storage containers and temperatures. Recipient records must be maintained for the purpose of tracing tissue post-transplantation. Biostem Life Sciences will not be liable for any damages, whether direct or indirect, special, incidental or consequential resulting from improper use of this allograft. The instructions for use are specific, and Biostem Life Sciences waives all responsibility associated with mishandling, inappropriately storing and/or not taking proper precautions with the allograft tissue included with this insert.

	Read attached information on product use
	To be used with prescription only
	One time use on one recipient
	Serial number and lot number in bar code
	Mfg date and expiration on product label